Predicting the risk of asthma attacks in children, adolescents and adults: protocol for a machine learning algorithm derived from a primary care-based retrospective cohort

被引:7
|
作者
Hussain, Zain [1 ]
Shah, Syed Ahmar [1 ,2 ]
Mukherjee, Mome [1 ,2 ]
Sheikh, Aziz [1 ,2 ,3 ]
机构
[1] Univ Edinburgh, Edinburgh Med Sch, Usher Inst, Edinburgh, Midlothian, Scotland
[2] Univ Edinburgh, Asthma UK Ctr Appl Res AUKCAR, Edinburgh, Midlothian, Scotland
[3] Univ Edinburgh, Div Community Hlth Sci, Edinburgh, Midlothian, Scotland
来源
BMJ OPEN | 2020年 / 10卷 / 07期
基金
英国科研创新办公室;
关键词
health informatics; public health; epidemiology; asthma;
D O I
10.1136/bmjopen-2019-036099
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Most asthma attacks and subsequent deaths are potentially preventable. We aim to develop a prognostic tool for identifying patients at high risk of asthma attacks in primary care by leveraging advances in machine learning. Methods and analysis Current prognostic tools use logistic regression to develop a risk scoring model for asthma attacks. We propose to build on this by systematically applying various well-known machine learning techniques to a large longitudinal deidentified primary care database, the Optimum Patient Care Research Database, and comparatively evaluate their performance with the existing logistic regression model and against each other. Machine learning algorithms vary in their predictive abilities based on the dataset and the approach to analysis employed. We will undertake feature selection, classification (both one-class and two-class classifiers) and performance evaluation. Patients who have had actively treated clinician-diagnosed asthma, aged 8-80 years and with 3 years of continuous data, from 2016 to 2018, will be selected. Risk factors will be obtained from the first year, while the next 2 years will form the outcome period, in which the primary endpoint will be the occurrence of an asthma attack. Ethics and dissemination We have obtained approval from OPCRD's Anonymous Data Ethics Protocols and Transparency (ADEPT) Committee. We will seek ethics approval from The University of Edinburgh's Research Ethics Group (UREG). We aim to present our findings at scientific conferences and in peer-reviewed journals.
引用
收藏
页数:7
相关论文
共 48 条
  • [41] Maximization of the usage of coronary CTA derived plaque information using a machine learning based algorithm to improve risk stratification; insights from the CONFIRM registry
    van Rosendael, Alexander R.
    Maliakal, Gabriel
    Kolli, Kranthi K.
    Beecy, Ashley
    Al'Aref, Subhi J.
    Dwivedi, Aeshita
    Singh, Gurpreet
    Panday, Mohit
    Kumar, Amit
    Ma, Xiaoyue
    Achenbach, Stephan
    Al-Mallah, Mouaz H.
    Andreini, Daniele
    Bax, Jeroen J.
    Berman, Daniel S.
    Budoff, Matthew J.
    Cademartiri, Filippo
    Callister, Tracy Q.
    Chang, Hyuk-Jae
    Chinnaiyan, Kavitha
    Chow, Benjamin J. W.
    Cury, Ricardo C.
    DeLago, Augustin
    Feuchtner, Gudrun
    Hadamitzky, Martin
    Hausleiter, Joerg
    Kaufman, Philipp A.
    Kim, Yong-Jin
    Leipsic, Jonathon A.
    Maffei, Erica
    Marques, Hugo
    Pontone, Gianluca
    Raff, Gilbert L.
    Rubinshtein, Ronen
    Shaw, Leslee J.
    Villines, Todd C.
    Gransar, Heidi
    Lu, Yao
    Jones, Erica C.
    Pena, Jessica M.
    Lin, Fay Y.
    Min, James K.
    JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY, 2018, 12 (03) : 204 - 209
  • [42] A machine learning algorithm-based model for predicting the risk of non-suicidal self-injury among adolescents in western China: A multicentre cross-sectional study
    Zhong, Yunling
    He, Jinlong
    Luo, Jing
    Zhao, Jiayu
    Cen, Yu
    Song, Yuqin
    Wu, Yuhang
    Lin, Cen
    Pan, Lu
    Luo, Jiaming
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 345 : 369 - 377
  • [43] Utilizing machine learning for survival analysis to identify risk factors for COVID-19 intensive care unit admission: A retrospective cohort study from the United Arab Emirates
    AlShehhi, Aamna
    Almansoori, Taleb M.
    Alsuwaidi, Ahmed R.
    Alblooshi, Hiba
    PLOS ONE, 2024, 19 (01):
  • [44] Effectiveness of allergen immunotherapy (AIT) under real life conditions from a german retrospective cohort study in children, adolescents and adults with house dust mite (HDM) induced allergic rhinitis (AR) and asthma (AA)
    Moesges, R.
    Richter, H.
    Sager, A.
    Mueller, T.
    ALLERGY, 2023, 78
  • [45] Machine Learning Methods Using Artificial Intelligence Deployed on Electronic Health Record Data for Identification and Referral of At-Risk Patients From Primary Care Physicians to Eye Care Specialists: Retrospective, Case-Controlled Study
    Young, Joshua A.
    Chang, Chin-Wen
    Scales, Charles W.
    Menon, Saurabh, V
    Holy, Chantal E.
    Blackie, Caroline Adrienne
    JMIR AI, 2024, 3
  • [46] Enhanced Cardiovascular Risk Prediction of Calcium Scoring Computed Tomography Scans by Incorporating Pericardial Fat Characteristics: A Machine Learning Gradient Boost Analysis of Data Derived from a Deep Learning Segmentation Model of a Community-Based Cohort
    Mahmoudi, Elham
    Lopez-Jimenez, Francisco
    Medina, Betsy
    Medina-Inojosa, Jose
    Erickson, Bradley
    CIRCULATION, 2024, 150
  • [47] Nivolumab and Brentuximab Vedotin (BV)-Based, Response-Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study
    Cole, Peter D.
    Mauz-Koerholz, Christine
    Mascarin, Maurizio
    Michel, Gerard
    Cooper, Stacy
    Beishuizen, Auke
    Leger, Kasey J.
    Amoroso, Loredana
    Buffardi, Salvatore
    Rigaud, Charlotte
    Puhlmann, Markus
    Francis, Stephen
    Sacchi, Mariana
    Drachtman, Richard A.
    Harker-Murray, Paul
    Leblanc, Thierry
    Daw, Stephen
    Kelly, Kara M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S245 - S246
  • [48] Nivolumab (nivo) and brentuximab vedotin (BV)-based, response-adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis of the R2 cohort of the phase 2 CheckMate 744 study
    Mauz-Koerholz, C.
    Cole, P. D.
    Mascarin, M.
    Michel, G.
    Cooper, S.
    Beishuizen, A.
    Leger, K. J.
    Amoroso, L.
    Buffardi, S.
    Rigaud, C.
    Puhlmann, M.
    Francis, S.
    Sacchi, M.
    Drachtman, R. A.
    Harker-Murray, P.
    Leblanc, T.
    Daw, S.
    Kelly, K. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 89 - 90